Stem definition | Drug id | CAS RN |
---|---|---|
4921 | 133865-89-1 |
Dose | Unit | Route |
---|---|---|
75 | mg | O |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 2.19 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.17 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 21.67 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 20, 2019 | PMDA | Meiji Seika Pharma Co., Ltd. | |
March 21, 2017 | FDA | NEWRON PHARMS US INC | |
Dec. 18, 2014 | EMA | Zambon SpA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dyskinesia | 81.38 | 53.03 | 23 | 440 | 27838 | 50576823 |
Parkinsonism hyperpyrexia syndrome | 62.22 | 53.03 | 8 | 455 | 128 | 50604533 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hallucination | 53.31 | 44.32 | 21 | 405 | 44691 | 29529410 |
Freezing phenomenon | 46.95 | 44.32 | 9 | 417 | 1254 | 29572847 |
Dyskinesia | 44.79 | 44.32 | 15 | 411 | 20046 | 29554055 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dyskinesia | 95.81 | 47.47 | 31 | 848 | 39357 | 64458496 |
On and off phenomenon | 64.31 | 47.47 | 13 | 866 | 2506 | 64495347 |
Bradykinesia | 62.06 | 47.47 | 15 | 864 | 6545 | 64491308 |
Hallucination | 60.27 | 47.47 | 26 | 853 | 72762 | 64425091 |
Freezing phenomenon | 57.93 | 47.47 | 11 | 868 | 1535 | 64496318 |
Parkinsonism hyperpyrexia syndrome | 54.80 | 47.47 | 8 | 871 | 222 | 64497631 |
None
Source | Code | Description |
---|---|---|
ATC | N04BD03 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Monoamine oxidase B inhibitors |
FDA MoA | N0000175761 | Monoamine Oxidase-B Inhibitors |
FDA EPC | N0000175762 | Monoamine Oxidase Type B Inhibitor |
FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Parkinson's disease | indication | 49049000 | DOID:14330 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.92 | acidic |
pKa2 | 7.54 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 100MG BASE | XADAGO | MDD US | N207145 | March 21, 2017 | RX | TABLET | ORAL | 8278485 | June 8, 2027 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES |
EQ 50MG BASE | XADAGO | MDD US | N207145 | March 21, 2017 | RX | TABLET | ORAL | 8278485 | June 8, 2027 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES |
EQ 100MG BASE | XADAGO | MDD US | N207145 | March 21, 2017 | RX | TABLET | ORAL | 8076515 | Dec. 10, 2028 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES |
EQ 50MG BASE | XADAGO | MDD US | N207145 | March 21, 2017 | RX | TABLET | ORAL | 8076515 | Dec. 10, 2028 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES |
EQ 100MG BASE | XADAGO | MDD US | N207145 | March 21, 2017 | RX | TABLET | ORAL | 8283380 | March 21, 2031 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES |
EQ 50MG BASE | XADAGO | MDD US | N207145 | March 21, 2017 | RX | TABLET | ORAL | 8283380 | March 21, 2031 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 100MG BASE | XADAGO | MDD US | N207145 | March 21, 2017 | RX | TABLET | ORAL | March 21, 2022 | NEW CHEMICAL ENTITY |
EQ 50MG BASE | XADAGO | MDD US | N207145 | March 21, 2017 | RX | TABLET | ORAL | March 21, 2022 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Amine oxidase [flavin-containing] B | Enzyme | INHIBITOR | Ki | 6.35 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Sodium channel protein type 9 subunit alpha | Ion channel | IC50 | 4.48 | CHEMBL | |||||
Amine oxidase [flavin-containing] A | Enzyme | IC50 | 4.35 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | IC50 | 7.71 | CHEMBL | |||||
Amine oxidase [flavin-containing] B | Enzyme | IC50 | 7.59 | CHEMBL | |||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5.09 | CHEMBL |
ID | Source |
---|---|
90ENL74SIG | UNII |
D10158 | KEGG_DRUG |
202825-46-5 | SECONDARY_CAS_RN |
4036707 | VANDF |
C1098261 | UMLSCUI |
CHEBI:134718 | CHEBI |
SAG | PDB_CHEM_ID |
CHEMBL396778 | ChEMBL_ID |
131682 | PUBCHEM_CID |
DB06654 | DRUGBANK_ID |
CHEMBL48582 | ChEMBL_ID |
8013 | INN_ID |
C092797 | MESH_SUPPLEMENTAL_RECORD_UI |
8291 | IUPHAR_LIGAND_ID |
1922448 | RXNORM |
241367 | MMSL |
d08444 | MMSL |
016557 | NDDF |
016558 | NDDF |
718852000 | SNOMEDCT_US |
763521008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Xadago | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27505-110 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 31 sections |
Xadago | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27505-111 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 31 sections |